Latest Financial Performance News

Genesis Minerals has reported a remarkable fourfold increase in net profit after tax to A$238 million for the first half of FY26, driven by a 58% rise in gold production and robust margins. The company’s strong cash position and accelerated growth plans position it well for the year ahead.

Emeco Holdings Limited has reported a solid 15% increase in net profit for the half year ending December 2025, alongside a 9% rise in revenue, while opting to maintain a no-dividend payout policy.

Transurban Group posted robust half-year results for December 2025, with revenue climbing 8.1% and profit rebounding to $343 million. The company also declared a 34-cent interim distribution, underpinned by strong cash flow and key project milestones.

Telstra Group Limited reported solid half-year results for December 2025, with revenue and profit growth underpinning a higher dividend and an expanded share buy-back program. The company’s Connected Future 30 strategy continues to drive operational momentum amid disciplined cost management.

Auckland International Airport reported a 6% rise in underlying profit for the first half of FY26, driven by passenger growth and key infrastructure projects. The airport also narrowed its full-year guidance while navigating global fleet capacity challenges.

Spheria Emerging Companies Limited has reported a solid 16.8% increase in profit after tax for the half-year ending December 2025, alongside a strategic shift introducing monthly fully franked dividends.

Infragreen Group Limited reports a remarkable turnaround with a statutory net profit of A$3.64 million for H1 2025 and declares its inaugural interim dividend, underscoring confidence in its sustainable infrastructure investments.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Sports Entertainment Group Limited reported a robust half-year ending December 2025, with revenues climbing 28% and underlying EBITDA soaring 78%, driven by strong media and complementary services growth. The company also finalised its Perth Wildcats divestment, boosting cash reserves.